NEXT Oncology, an Avacare business

NEXT Oncology, an Avacare business NEXT Oncology, an Avacare business, strives to provide exceptional care, the latest cancer treatments, and a community devoted to finding a cure.

Congratulations to our colleagues at Cartography Biosciences for dosing the first patient in its Phase I trial. Learn mo...
03/18/2026

Congratulations to our colleagues at Cartography Biosciences for dosing the first patient in its Phase I trial.

Learn more here:

Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced...

03/12/2026
March is Month - and early detection matters. Know the facts and talk to your physician about screening.
03/02/2026

March is Month - and early detection matters. Know the facts and talk to your physician about screening.

This World Cancer Day, we honor the patients and researchers driving progress in cancer care. Phase 1 clinical trials ar...
02/04/2026

This World Cancer Day, we honor the patients and researchers driving progress in cancer care. Phase 1 clinical trials are a vital first step in translating promising science into hope.

These preliminary results from Aprea Therapeutics are encouraging - congratulations! We are proud to be part of this tri...
02/03/2026

These preliminary results from Aprea Therapeutics are encouraging - congratulations! We are proud to be part of this trial.

“These early single-agent data demonstrate that APR-1051 has clinical activity as a single agent. The observation of a partial response on the first scan, together with a decrease in tumor marker at this dose level, supports continued clinical evaluation of APR-1051," commented NEXT Oncology's founder Anthony Tolcher.

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response...

Each year in the United States, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of thi...
01/27/2026

Each year in the United States, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Be informed, and learn more here.

While NCCC is focused on cervical health and cervical cancer prevention all year long, Cervical Health Awareness Month in January is a time where we want to get as many people involved as we can. The World Health Organization has a plan for the elimination of cervical cancer through vaccination and....

This Cervical Cancer Awareness Month, we recognize the importance of prevention, research, and continued progress in can...
01/21/2026

This Cervical Cancer Awareness Month, we recognize the importance of prevention, research, and continued progress in cancer care.



Did you know it’s cervical cancer awareness month? Learn more about cervical cancer here.
01/13/2026

Did you know it’s cervical cancer awareness month? Learn more about cervical cancer here.

Learn about symptoms, risk factors, screening, and treatment.

Thank you to the American Association for Cancer Research (AACR) for this fascinating roundtable on dose optimization f...
12/05/2025

Thank you to the American Association for Cancer Research (AACR) for this fascinating roundtable on dose optimization featuring our own Anthony Tolcher.

Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.

Address

2829 Babcock, Suite 300
San Antonio, TX
78229

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when NEXT Oncology, an Avacare business posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to NEXT Oncology, an Avacare business:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

About Next Oncology

Our mission is to transform the industry though the development of the next breakthrough in cancer research through high quality Phase 1 clinical pharmacology trials.

NEXT Oncology, founded by Anthony W. Tolcher, M.D., FRCPC, is a Phase 1 center dedicated to providing options for advanced cancer patients and advancing cancer research. Dr. Tolcher’s passion for research and the community lays the foundation for an international brand committed to finding the next breakthrough.

Dr. Anthony Tolcher is a medical oncologist and co-founder of NEXT. He is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option that includes clinical trials of new agents and therapies. Dr. Tolcher is proud that at NEXT Oncology the team scours the world to bring the best new agents back to our patients and centers.

This is not a job for Dr. Tolcher, it is his passion.